Consequently, a therapeutic strategy involving the modulation of KLF5 or miR-152-3p in conjunction with stem cell therapy emerges as a promising and innovative approach for myocardial infarction (MI) treatment. The gene discussed is KLF5; the disease is myocardial infarction.